1. NMS-P088, a CSF-1R, FLT3 and KIT inhibitor with outstanding activity on gatekeeper resistance mutations, high tolerability, and potential for combination therapies. (December 2016) Authors: Ardini, E.; Lombardi Borgia, A.; Texido, G.; Alzani, R.; Avanzi, N.; Amboldi, N.; Cribioli, S.; Mancini, L.; Casero, D.; Pastori, W.; Montemartini, M.; Montagnoli, A.; Donati, D.; Galvani, A.; Isacchi, A.; Ciomei, M. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S127 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗